Rigel Pharmaceuticals Inc (NASDAQ:RIGL)

1.11
Delayed Data
As of Sep 23
 -0.055 / -4.74%
Today’s Change
0.64
Today|||52-Week Range
3.91
-58.30%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$215.2M

Company Description

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Contact Information

Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard
South San Francisco California 94080-1985
P:(650) 624-1100
Investor Relations:

Employees

Shareholders

Mutual fund holders44.92%
Other institutional41.74%
Individual stakeholders12.11%

Top Executives

Raul R. RodriguezPresident, Chief Executive Officer & Director
Dean L. SchornoChief Financial Officer & Executive Vice President
Wolfgang DummerChief Medical Officer & Executive Vice President
David SantosChief Commercial Officer & Executive VP
Joseph LasagaSenior Vice President-Corporate Development